603883.SS

Full House

LBX Pharmacy Chain Joint Stock Company · Healthcare · China · $1.6B cap · $34.9M/day traded

CNY 14.91 +0.7% · close 17 Nov · scored 18 Nov

Full House: Strong business, sensible price, and the market agrees.

97
Score
Get score and insider alerts
Quality
63
Value
74
Momentum
73

As of 18 Nov 2026, the MoatMap Score for LBX Pharmacy Chain Joint Stock Company (603883.SS) is 97/100, ranked against 25,000+ stocks in 38 markets (Quality 63, Value 74, Momentum 73, each scored against its sector).

Does the score work? Each tenth of the ranking, tracked monthly. See the record →

P/E (TTM)
23.4x
peers 26.6x
ROE
9.0%
peers 4.0%
D/E
0.5x
peers 0.2x
Dividend %
4.0%
trailing yield

ABOUT LBX PHARMACY CHAIN JOINT STOCK COMPANY

Read

LBX Pharmacy Chain Joint Stock Company operates a nationwide chain of retail pharmacies selling prescription drugs, OTC medicines, and healthcare products. The company is one of China's largest pharmacy chains with over 10,000 stores, leveraging strong purchasing power and brand recognition. It is a leading consolidator in China's highly fragmented pharmaceutical retail market, expanding rapidly through a mix of organic growth, acquisitions, and franchising.

FINANCIAL SUMMARY (CNY)

Year20212022202320242025CAGRTTM2026E2027EFwd CAGR
Income and shares
Revenue15.7B20.2B22.4B22.4B22.2B9.1%22.8B23.4B25.7B7.5%
Net margin4.3%3.9%4.1%2.3%1.7%-2.6 pts————
EPS (CNY)1.21.01.20.70.5-20.2%0.60.91.255.0%
Share count—760.4M760.4M760.2M758.9M-0.1%766.6M———
Balance sheet
Debt—5.5B5.0B5.8B4.6B-5.8%3.8B———
Equity4.4B6.5B6.7B6.6B6.5B10.7%————
Debt/equity—0.8x0.8x0.9x0.7x-0.1x————
Cash flow
Op. cash flow2.3B2.3B2.7B2.0B3.1B8.1%3.2B———
Cash flow margin14.6%11.5%12.2%9.1%14.1%-0.5 pts14.0%———
Investing CF-2.0B-1.5B-761.3M-627.9M-236.7M—————
Financing CF-413.2M-142.6M-2.4B-1.3B-2.7B—————
PRICE (1Y) · CNY+14.3%
13.013.514.014.515.030 Sep28 Oct17 Nov
SMA 50SMA 200

Price checkTurning upExperimental

46% above its 52-week low and back above a rising 50-day average since 11 Nov 2026.

SwingsCalm

Calmer than 75% of stocks we rank over the past year (volatility 29% a year).

How this is worked out

The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.

  • Still falling: It set a new 52-week low in the last two weeks, after a deep fall.
  • Finding a floor: It fell hard, but has set no new low for more than two weeks.
  • Turning up (this stock): It has climbed off its low and is back above a rising 50-day average.
  • In an uptrend: It is near its 52-week high and above its 200-day average.
  • No clear trend: None of the above: no recent deep fall and no steady climb.
  • No read yet: Not enough price history yet: it needs a year of trading.

In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.

The exact rules

Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.

What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.

Calm is not safe: a calm stock can still slide steadily.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
CNY 14.91
RSI (14)
55.4
52-Week Range-13.1% from high
Low CNY 10.19High CNY 17.15

SCORE BREAKDOWN

Quality
63
ROIC
10.9%71.6
ROE
9.0%66.0
GP/Assets
36.7%74.4
Op. Margin
5.5%54.1
FCF/Assets
14.6%93.2
Piotroski
668.8
Int. Cover
6.8x56.1
D/E Ratio
0.53x27.7
Current Ratio
0.85x7.3
Value
74
P/E (TTM)
23.4x50.2
EV/EBITDA
9.4x70.0
P/FCF
3.7x94.8
P/B
1.6x66.2
P/S
0.5x92.1
Div Yield
4.0%82.5
Momentum
73
52W High %
87%80.4
RS 6M
35%86.1
SMA 50/200
1.06x74.6
EPS Rev 4W
+1.8%79.1
EPS Rev 12W
-8.8%14.9
EPS Improve
+101%75.6
Q Growth
31%66.0

FUNDAMENTALS

Market Cap
$1.6B
P/E (Forward)
11.7x
Gross Margin
32.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 603883.SS are excluded.

TickerCompanyMkt CapScore
603883.SSLBX Pharmacy Chain Joint Stock Company(you)$1.6B97
002727.SZYixintang Pharmaceutical Group Co., Ltd.$1.1B98
603233.SSDaShenLin Pharmaceutical Group Co., Ltd.$3.2B97
603939.SSYifeng Pharmacy Chain Co., Ltd.$4.6B97
1345.HKShanghai Pioneer Holding Ltd$293M93
301408.SZAnhui Huaren Health Pharmaceutical Co., Ltd.$816M71
9885.HKYSB Inc.$313M88
6618.HKJD Health International Inc.$15.3B85
301017.SZShuYu Civilian Pharmacy Corp., Ltd.$860M53
002788.SZLuyan Pharma Co.,Ltd.$568M56

Peer medians: ROE 4.0% · P/E 26.6x · Gross margin 53.1%

Company Deep Dive

A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.

Request Deep Dive(50 Feathers)

LBX Pharmacy Chain Joint Stock Company (603883.SS): Stock Score Summary

LBX Pharmacy Chain Joint Stock Company (603883.SS) has a MoatMap Score of 97/100 based on Quality (63/100), Value (74/100), and Momentum (73/100) factor scores.

LBX Pharmacy Chain Joint Stock Company operates a nationwide chain of retail pharmacies selling prescription drugs, OTC medicines, and healthcare products. The company is one of China's largest pharmacy chains with over 10,000 stores, leveraging strong purchasing power and brand recognition. It is a leading consolidator in China's highly fragmented pharmaceutical retail market, expanding rapidly through a mix of organic growth, acquisitions, and franchising.

Director dealings

From 10 Mar 2026 to 18 Nov 2026, MoatMap's records hold no purchases or sales of LBX Pharmacy Chain Joint Stock Company (603883.SS) shares by its directors.

603883.SS insider filings, last 180 days

Key Financial Metrics

PriceCNY 14.91
Market Cap$1.6B
P/E (TTM)23.38
P/E (Forward)11.66
Price/Book1.62
Return on Equity9.0%
Return on Invested Capital10.9%
Debt/Equity0.53x
Gross Margin32.0%
Operating Margin5.5%
Revenue Growth6.7%
Dividend Yield4.0%
Free Cash Flow$434M

LBX Pharmacy Chain Joint Stock Company operates in the Pharmaceutical Retailers industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is LBX Pharmacy Chain Joint Stock Company’s (603883.SS) MoatMap Score?
The MoatMap Score for LBX Pharmacy Chain Joint Stock Company (603883.SS) is 97/100. It is a composite of Quality (63), Value (74), and Momentum (73), each scored against its sector. The composite is then ranked across MoatMap’s universe of 25,000+ stocks.
Does LBX Pharmacy Chain Joint Stock Company have an economic moat?
LBX Pharmacy Chain Joint Stock Company (603883.SS) has a Quality factor score of 63/100. Quality blends several measures of profitability and financial strength, led by gross profit to assets, return on invested capital and free cash flow to assets. A high score describes the financial record a durable advantage tends to leave; it does not prove a moat.
What sector is LBX Pharmacy Chain Joint Stock Company in?
LBX Pharmacy Chain Joint Stock Company (603883.SS) operates in the Healthcare sector, specifically the Pharmaceutical Retailers industry (China).